Michael R Charlton
Overview
Explore the profile of Michael R Charlton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
3430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rinella N, Charlton W, Reddy G, Diaz P, Charlton M
JAMA Netw Open
. 2024 Oct;
7(10):e2439846.
PMID: 39422910
Importance: Liver disease is a leading cause of mortality in the US. Liver transplant can be a lifesaving procedure for patients with severe liver disease. Objective: To assess temporal trends...
2.
Fishman J, Kim Y, Charlton M, Smith Z, OConnell T, Bercaw E
Adv Ther
. 2024 Sep;
41(11):4172-4190.
PMID: 39292422
Introduction: As of March 2024, resmetirom is the first and only therapy approved in the United States (US) for the treatment of adults with non-cirrhotic nonalcoholic steatohepatitis (NASH) with moderate-to-advanced...
3.
Noureddin M, Charlton M, Harrison S, Bansal M, Alkhouri N, Loomba R, et al.
Clin Gastroenterol Hepatol
. 2024 Jul;
22(12):2367-2377.
PMID: 39038768
Metabolic dysfunction-associated steatotic liver disease affects 1 in 4 people in the United States and western Europe, with an important proportion developing metabolic dysfunction-associated steatohepatitis (MASH), the progressive subtype of...
4.
Allen A, Younossi Z, Diehl A, Charlton M, Lazarus J
Nat Rev Gastroenterol Hepatol
. 2024 Jun;
21(10):726-738.
PMID: 38834817
Since 1980, the cumulative effort of scientists and health-care stakeholders has advanced the prerequisites to address metabolic dysfunction-associated steatotic liver disease (MASLD), a prevalent chronic non-communicable liver disease. This effort...
5.
Fishman J, OConnell T, Parrinello C, Woolley J, Bercaw E, Charlton M
J Health Econ Outcomes Res
. 2024 Feb;
11(1):32-43.
PMID: 38370007
Nonalcoholic fatty liver disease (NAFLD) is believed to be the most common chronic liver disease worldwide. Therapies are under development for nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, such...
6.
Harrison S, Bedossa P, Guy C, Schattenberg J, Loomba R, Taub R, et al.
N Engl J Med
. 2024 Feb;
390(6):497-509.
PMID: 38324483
Background: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH...
7.
Odenwald M, Lin H, Lehmann C, Dylla N, Cole C, Mostad J, et al.
Nat Microbiol
. 2023 Oct;
8(11):2033-2049.
PMID: 37845315
Progression of chronic liver disease is precipitated by hepatocyte loss, inflammation and fibrosis. This process results in the loss of critical hepatic functions, increasing morbidity and the risk of infection....
8.
Fei N, Miyoshi S, Hermanson J, Miyoshi J, Xie B, DeLeon O, et al.
bioRxiv
. 2023 Jan;
PMID: 36712061
Nonalcoholic fatty liver disease (NAFLD) is multifactorial in nature, affecting over a billion people worldwide. The gut microbiome has emerged as an associative factor in NAFLD, yet mechanistic contributions are...
9.
Wang Y, Crittenden D, Eng C, Zhang Q, Guo P, Chung D, et al.
Clin Pharmacol Drug Dev
. 2021 Jul;
10(10):1198-1208.
PMID: 34302449
TERN-101 is a nonsteroidal farnesoid X-receptor agonist being developed for the treatment of nonalcoholic steatohepatitis (NASH). We assessed the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TERN-101 capsule and tablet...
10.
Kim T, Banini B, Asumda F, Campbell N, Hu C, Moser C, et al.
Am J Physiol Gastrointest Liver Physiol
. 2020 Jul;
319(3):G333-G344.
PMID: 32683952
Sulfatase 2 (SULF2) is a heparan sulfate editing enzyme that regulates the milieu of growth factors and cytokines involved in a variety of cellular processes. We used a murine model...